EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Plain Language Summary on Assessing the Long-Term Effectiveness of Cladribine Tablets in People Living with Relapsing Multiple Sclerosis: The CLASSIC-MS Study

Gavin Giovannoni, Alexey Boyko, Jorge Correale, Gilles Edan, Mark S Freedman, Xavier Montalban, Kottil Rammohan, Dusan Stefoski, Bassem Yamout, Thomas Leist, Aida Aydemir, Laszlo Borsi und 1 weitere

Neurodegenerative Disease Management · 2023

DOI: 10.2217/nmt-2023-0018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurodegenerative Disease Management, 2023. Verfasst von Gavin Giovannoni und 12 weiteren Autor:innen. Beteiligte Einrichtung: Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

WHAT IS THIS SUMMARY ABOUT?: Previous studies have shown that people living with multiple sclerosis (MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studies. WHAT WERE THE RESULTS?: Results showed that people treated with cladribine tablets maintained their mobility (the ability to move freely) for longer and experienced other positive effects long after their treatment ended, including being less likely to need further treatment for their MS. WHAT DO THE RESULTS MEAN?: The results obtained from CLASSIC-MS show that the benefits of taking cladribine tablets carry on even when patients stop taking the treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingHumansCladribineImmunosuppressive AgentsTabletsRecurrence

Stichwörter der Autor:innen

cladribine tablets (Mavenclad®)lay summarymobilitymultiple sclerosisrelapses

Substanzen

CladribineImmunosuppressive AgentsTablets

Autor:innen und Institutionen

  • Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
  • Pirogov Russian National Research Medical University, Department of Neurology, Neurosurgery & Medical Genetics, Federal Center of Brain Research & Neurotechnologies, Moscow, Russia.
  • Department of Neurology, FLENI Institute, Buenos Aires, Argentina.
  • Department of Neurology, University Hospital of Rennes, Rennes, France.
  • University of Ottawa, Department of Medicine & the Ottawa Hospital Research Institute, Ottawa, ON, Canada.
  • Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain.

Zitieren

APA

Giovannoni, G., Boyko, A., Correale, J., Edan, G., Freedman, M. S., Montalban, X., Rammohan, K., Stefoski, D., Yamout, B., Leist, T., Aydemir, A., Borsi, L., & di Cantogno, E. V. (2023). A Plain Language Summary on Assessing the Long-Term Effectiveness of Cladribine Tablets in People Living with Relapsing Multiple Sclerosis: The CLASSIC-MS Study. Neurodegenerative Disease Management. https://doi.org/10.2217/nmt-2023-0018

Vancouver

Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, et al. A Plain Language Summary on Assessing the Long-Term Effectiveness of Cladribine Tablets in People Living with Relapsing Multiple Sclerosis: The CLASSIC-MS Study. Neurodegenerative Disease Management. 2023. doi:10.2217/nmt-2023-0018

BibTeX
@article{Giovannoni2023,
  author = {Giovannoni, Gavin and Boyko, Alexey and Correale, Jorge and Edan, Gilles and Freedman, Mark S and Montalban, Xavier and Rammohan, Kottil and Stefoski, Dusan and Yamout, Bassem and Leist, Thomas and Aydemir, Aida and Borsi, Laszlo and di Cantogno, Elisabetta Verdun},
  title = {A Plain Language Summary on Assessing the Long-Term Effectiveness of Cladribine Tablets in People Living with Relapsing Multiple Sclerosis: The CLASSIC-MS Study},
  journal = {Neurodegenerative Disease Management},
  year = {2023},
  doi = {10.2217/nmt-2023-0018}
}
Kostenlos starten →